Get the Stockscreener App
4.23
0.71%
0.03
After Hours:
4.22
-0.01
-0.24%
Bioage Labs Inc stock is traded at $4.23, with a volume of 523.83K.
It is up +0.71% in the last 24 hours and down -1.17% over the past month.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
See More
Previous Close:
$4.20
Open:
$4.19
24h Volume:
523.83K
Relative Volume:
2.13
Market Cap:
$144.12M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+9.30%
1M Performance:
-1.17%
6M Performance:
-82.42%
1Y Performance:
+0.00%
1-Day Range:
$4.00
$4.23
1-Week Range:
$3.80
$4.26
52-Week Range:
$2.88
$26.62
Bioage Labs Inc Stock (BIOA) Company Profile
Name
Bioage Labs Inc
Sector
Phone
510-806-1445
Address
1445A SOUTH 50TH STREET, RICHMOND
Compare BIOA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
4.23 | 144.12M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
153.47 | 65.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 46.99B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.18 | 45.96B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.87 | 17.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
291.38 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Dec-10-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-09-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-21-24 | Initiated | Citigroup | Buy |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-21-24 | Initiated | Morgan Stanley | Overweight |
View All
Bioage Labs Inc Stock (BIOA) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
Investors who hold shares of BioAge Labs, Inc. (NASDAQ: BIOA) - openPR.com
Notice to Long-Term Shareholders of BioAge Labs, Inc. - GlobeNewswire
Notice to Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); Driven Bands Holdings - Bluefield Daily Telegraph
BioAge Labs, Inc. (BIOA): A Bull Case Theory - Insider Monkey
Grabar Law Office Investigates Claims on Behalf of - GlobeNewswire
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); NAPCO Security Technologies, Inc. (NASDAQ: NSSC); Treace Medical Concepts, Inc. (NASDAQ: TMCI); and Virtu Financial Inc. (NASDAQ: VI - TradingView
BIOA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that BioAge Labs, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPOHagens Berman - ACCESS Newswire
Several Insiders Invested In BioAge Labs Flagging Positive News - Yahoo Finance
Cautious Outlook on BioAge Labs Amid Promising Developments and High Risk - TipRanks
BioAge Labs, Inc.: Sell Rating Due to Discontinued Program and Uncertain Prospects - TipRanks
William Blair Sticks to Its Hold Rating for BioAge Labs, Inc. (BIOA) - The Globe and Mail
BioAge Labs Inc. (BIOA) reports earnings - Quartz
BioAge Labs, Inc. Advances NLRP3 Inhibitor BGE-102 and Forms Strategic Collaborations with Novartis and Lilly for Metabolic Diseases - Nasdaq
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the - Bluefield Daily Telegraph
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 - TradingView
BioAge Labs Lands Massive $550M Novartis Deal Despite Clinical Setback in 2024 Results - Stock Titan
Final Deadline for the BioAge Labs, Inc. Securities LawsuitContact the DJS Law Group to Discuss Your RightsBIOA - The Malaysian Reserve
BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit - PR Newswire
BIOA DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors - Bluefield Daily Telegraph
BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Bioage Labs principal accounting officer Barton Shane buys $47,376 in common stock By Investing.com - Investing.com South Africa
Bioage Labs principal accounting officer Barton Shane buys $47,376 in common stock - Investing.com
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs - Markets Insider
Lost Money on BioAge Labs, Inc. (BIOA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - GlobeNewswire
Lost Money on BioAge Labs, Inc. (BIOA)? Join Class Action Suit Seeking Recovery – Contact Levi ... - Bluefield Daily Telegraph
2025-03-10 | Shareholders that Lost Money on BioAge Labs, Inc. (BIOA) Should Contact Levi & Korsinsky About Pending Class ActionBIOA | NDAQ:BIOA | Press Release - Stockhouse Publishing
DEADLINE ALERT for REGN and BIOA: The Law Offices of Frank - GlobeNewswire
March 10, 2025 Filing Deadline in Securities Class ActionContact Kessler Topaz Meltzer & - FinancialContent
BIOA FINAL DEADLINE: BioAge Labs Investors are Encouraged - GlobeNewswire
Lost Money on BioAge Labs, Inc.(BIOA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
BIOA Final Opportunity to Lead BioAge Labs, Inc. Securities Fraud Lawsuit with the Schall Law Firm - themalaysianreserve.com
Investors in BioAge Labs, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your RightsBIOA - GuruFocus.com
BioAge Labs, Inc. Class Action: The Gross Law Firm Reminds BioAge Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025BIOA - PR Newswire
Levi & Korsinsky Reminds BioAge Labs, Inc. Investors of the Pend - GuruFocus
2025-03-09 | Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in BioAge Labs, Inc. LawsuitBIOA | NDAQ:BIOA | Press Release - Stockhouse Publishing
Class Action Filed Against BioAge Labs, Inc. (BIOA)March 10, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
BioAge Labs, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before March 10, 2025 to Discuss Your RightsBIOA - ACCESS Newswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs - StreetInsider
BIOA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds BioAge Labs, Inc. (BIOA) Investors of Filing Deadline in Class Action Lawsuit | StreetInsider.com - Financial Content
BIOA LEGAL NEWS: A Class Action was filed on behalf of BioAge Labs Investors - GlobeNewswire Inc.
BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit – Hagens Berman - GlobeNewswire
Faruqi & Faruqi Reminds BioAge Investors of the Pending Class Act - The National Law Review
BIOA Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of BioAge ... - Bluefield Daily Telegraph
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of BioAge Labs, Inc. (BIOA) Shareholders - GlobeNewswire
BIOA DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors ... - The Bakersfield Californian
Deadline Soon: BioAge Labs, Inc. (BIOA) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire
BIOA Deadline: Rosen Law Firm Urges BioAge Labs, Inc. (NASDAQ: BIOA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Joplin Globe
Cautious Outlook on BioAge Labs, Inc. Amid Program Discontinuation and Development Risks - TipRanks
Bioage Labs Inc Stock (BIOA) Financials Data
There is no financial data for Bioage Labs Inc (BIOA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.00%
1.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):